Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 369, Issue 1, 2004, Pages 69-77

  Gerloff, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Blood tissue barriers; Drug disposition; Efflux; Pharmacogenetics; Polymorphisms; Transmembrane transporters; Uptake

Indexed keywords

ABC TRANSPORTER; ACICLOVIR; AMANTADINE; BETA LACTAM ANTIBIOTIC; CAPTOPRIL; CARRIER PROTEIN; DESIPRAMINE; DIGOXIN; DIPEPTIDE; DOPAMINE; DRUG CARRIER; ESTRONE SULFATE; FEXOFENADINE; GLYCOPROTEIN P; GUANIDINE; MEMANTINE; METHOTREXATE; MONOCARBOXYLATE TRANSPORTER; NUCLEOSIDE TRANSPORTER; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; OUABAIN; PENICILLIN G; PRASTERONE SULFATE; PRAVASTATIN; PROCAINAMIDE; QUINIDINE; RIFAMPICIN; UNINDEXED DRUG; XENOBIOTIC AGENT;

ALLELE; CELL MEMBRANE TRANSPORT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; EXON; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; NONHUMAN; PHARMACOGENETICS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE DISTRIBUTION;

ANIMALS; HUMANS; MEMBRANE TRANSPORT PROTEINS; METABOLIC DETOXICATION, DRUG; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY; XENOBIOTICS;

EID: 0742269421     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-003-0813-5     Document Type: Review

References (76)

1. Arndt P et al (2001) Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol 281:110-115
2. Avdeef A (2001) Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem 1:277-351
3. Ayrton A, Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497
4. Borst P, Oude Elferink R (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592
5. Camenisch G et al (1996) Review of theoretical passive drug absorption models: historical background, recent development and limitations. Pharm Acta Helv 71:309-327
6. Cascorbi I et al (2001) Frequency of single nucleotide polymorphisms (SNPs) in the P-glycoprotein drug transporter MDR1 gene in Caucasians. Clin Pharmacol Ther 69:169-174
7. Cherrington NJ et al (2002) Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300:97-104
8. Cole SPC et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654
9. Conrad S et al (2001) Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671 V substitution. J Hum Genet 46:656-663
10. Conrad S et al (2002) A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12:321-330
11. Cordon-Cardo C et al (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287
12. Covitz KM et al (1998) Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry 37:15214-15221
13. Cvetkovic M et al (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871
14. De Lange EC et al (1998) BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharm Res 15:1657-1665
15. Dresser MJ et al (2001) Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 90:397-421
16. Fei YJ et al (1997) Identification of the histidyl residue obligatory for the catalytic activity of the human H+/peptide cotransporters PEPT1 and PEPT2. Biochemistry 36:452-460
17. Fellay J et al (2002) Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36
18. Fromm M (2002) The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54:1295-1310
19. Ganapathy ME et al (1995) Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem 270:25672-25677
20. Ganapathy V, Leibach FH (1986) Carrier mediated reabsorption of small peptides in renal proximal tubule. Am J Physiol 251: F945-F953
21. Gao M et al (1998) Multidrug resistance protein. J Biol Chem 273: 10733-10740
22. Gerloff T et al (2002) MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 54:610-616
23. Gorboulev V et al (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871-881
24. Greiner B et al (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153
25. Gründemann D et al (1994) Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549-552
26. Hagenbuch B, Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1-18
27. Han H et al (1998) 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 15:1154-1159
28. Hidalgo IJ et al (1995) Structural requirements for interaction with the oligopeptide transporter in Caco-2 cells. Pharm Res 12: 317-319
29. Higgins CF (2001) ABC transporters: physiology, structure and mechanism - an overview. Res Microbiol 152:205-210
30. Hipfner DR et al (1999) Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP. J Biol Chem 274:15420-15426
31. + natural killer cells. Pharmacogenetics 11:1-6
32. Hoffmeyer S et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478
33. Hsiang B et al (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161-37168
34. Hu M et al (1995) Mechanisms of transport of quinapril in Caco-2 cell monolayers: comparison with cephalexin. Pharm Res 12: 1120-1125
35. Iida A et al (2001) Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion transporting polypeptide, and three NADH:ubiquinone oxidoreductase flavoproteins. J Hum Genet 46:668-683
36. Ishizuka H et al (1998) Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther 287:37-42
37. Ito S et al (2001) Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175-184
38. Itoda M et al (2002) Polymorphisms in the ABCC2 (cMOAT/ MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab Dispos 30:363-364
39. Johne A et al (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72:584-594
40. Juranka PF et al (1989) P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3:2583-2592
41. Keppler D et al (1997) Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 378:787-791
42. Kerb R et al (2001) ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2:51-64
43. Kerb R et al (2002) Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12:591-595
44. Kim RB et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199
45. Konig J et al (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461:377-394
46. Koepsell H (1998) Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 60:243-266
47. Kruijtzer CM et al (2002) Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 7:516-530
48. Kullak-Ublick GA et al (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533
49. Lazar et al (2003) Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3). J Hum Genet 48:226-230
50. Leabman MK et al (2002) Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12:395-405
51. Lee VHL (2000) Membrane transporters. Eur J Pharm Sci 11:S41-S50
52. Meier PJ et al (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667-1677
53. Michalski C et al (2002) A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 277:43058-43063
54. Muller M (2001) 48 human ATP-binding cassette transporters. http://www.nutrigene.4t.com/humanabc.htm
55. Nishizato Y et al (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554-565
56. Nozawa T et al (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allelic frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804-813
57. Palm K et al (1996) Correlation of drug absorption with molecular surface properties. J Pharm Sci 85:32-39
58. Pang KS et al (1998) The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology 28:1341-1346
59. Pauli-Magnus C et al (2002) No effect of MDR1 C3435T polymorphism on disposition and CNS effects of loperamide [abstract]. Clin Pharmacol Ther 71:P72
60. Paulusma CC, Oude Elferink RP (1997) The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J Mol Med 75:420-428
61. Rao VV et al (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 96:3900-3905
62. Saito H et al (1997) Cloning and characterization of a pH-sensing regulatory factor that modulates transport activity of the human H+/peptide cotransporter, PEPT1. Biochem Biophys Res Commun 237:577-582
63. Sakaeda T et al (2001) MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18:1400-1404
64. Schaub TP et al (1997) Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol 8:1213-1221
65. Sellin JH (1996) The pathophysiology of diarrhea. In: Schultz SG, Adndreoli TE, Brown AM, Fambrough DM, Hoffman JF, Welsh MJ (eds) Molecular biology of membrane transport disorders. Plenum, New York, pp 541-563
66. Siegmund W et al (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72: 572-583
67. Stenberg P et al (2000) Virtual screening of intestinal drug permeability. J Control Release 65:231-243
68. Tamai I et al (2000) Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251-260
69. Tanigawara Y (2000) Role of P-glycoprotein in drug disposition. Ther Drug Monit 22:137-140
70. Temple CS, Boyd CA (1998) Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter. Biochim Biophys Acta 1373:277-281
71. Terada T et al (1996) Identification of the histidine residues involved in substrate recognition by a rat H+/peptide cotransporter, PEPT1. FEBS Lett 394:196-200
72. Tirona RG et al (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 276:35669-35675
73. Urtti A et al (2001) Genomic structure of proton-coupled oligopeptide transporter hPEPT1 and pH sensing regulatory splice variant. AAPS Pharm Sci 3:E6
74. Van Aubel RA et al (2000) Expression and immunolocalization of multidrug resistance protein 2 in rabbit small intestine. Eur J Pharmacol 400:195-198
75. Van Montfoort JE et al (2001) Comparison of 'type I' and 'type II' organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther 298:110-115
76. Wacher VJ et al (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134